Expression of Concern: Head Lice of Pygmies Reveal the Presence of Relapsing Fever Borreliae in the Republic of Congo. [PDF]
PLOS Neglected Tropical Diseases Editors.
europepmc +1 more source
Genomic and structural analysis of major antigenic proteins' variability in the human relapsing fever spirochete <i>Borrelia persica</i>. [PDF]
Shwartz D +6 more
europepmc +1 more source
Historical overview and update on relapsing fever group Borrelia in Latin America. [PDF]
Faccini-Martínez ÁA +6 more
europepmc +1 more source
Summary To assess the cost‐effectiveness of blinatumomab plus chemotherapy for paediatric patients from Hong Kong public healthcare provider's perspective, a 10‐year Markov model was designed to simulate outcomes in paediatric patients with newly diagnosed standard‐risk B‐cell ALL at: (1) average risk and (2) high risk of relapse.
Mingjun Rui +7 more
wiley +1 more source
Unusual presentation of complicated relapsing fever with spontaneous hemoperitoneum mimicking surgical acute abdomen: a case report. [PDF]
Tesfay YG +6 more
europepmc +1 more source
Tick borne relapsing fever - a systematic review and analysis of the literature. [PDF]
Jakab Á +3 more
europepmc +1 more source
Alkalinised lidocaine as an anaesthetic before onabotulinumtoxinA injections. a randomised trial
Objectives To evaluate the effect of intravesical alkalinised lidocaine as an anaesthetic treatment on procedural pain during intradetrusor onabotulinumtoxinA (BTX‐A) injections for overactive bladder. Patients and Methods This single‐centre, randomised, double‐blind, placebo‐controlled two period crossover trial was conducted on women scheduled for ...
Meryam El Issaoui +2 more
wiley +1 more source
Genome report: whole-genome assembly of the relapsing fever tick Ornithodoros turicata Dugès (Acari: Argasidae). [PDF]
Tietjen M +10 more
europepmc +1 more source
Expression of Concern: Tick-borne relapsing fever Borreliosis, a major public health problem overlooked in Senegal. [PDF]
PLOS Neglected Tropical Diseases Editors.
europepmc +1 more source
A whole‐exome sequencing–based mutational signature biomarker (MSBM) identified an HRD‐enriched population in advanced ovarian cancer. In a phase II trial, olaparib maintenance suggested clinically meaningful PFS benefit without bevacizumab, supporting MSBM as a complementary HRD assessment approach.
Katsutoshi Oda +20 more
wiley +1 more source

